<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063880</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001052</org_study_id>
    <secondary_id>2R01HD023412-21</secondary_id>
    <nct_id>NCT02063880</nct_id>
  </id_info>
  <brief_title>Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)</brief_title>
  <acronym>PUSH</acronym>
  <official_title>Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children
      will be randomized to randomized to urgent (&lt;48 hours) versus early antiretroviral therapy
      (7-14 days). This trial will be unblinded.

      Population: Hospitalized HIV-1 infected children who are antiretroviral therapy (ART) naïve ≤
      12 years of age.

      Sample size: 360 children will be randomized (180 per arm).

      Treatment: All infants will be treated with ART according to World Health Organization (WHO)
      and Kenyan national guidelines.

      Study duration: Enrollment into the study will occur over the course of 36-48 months and each
      infant will be routinely followed for a maximum of 6 months.

      Study site: Kenyan hospitals.

      Primary hypothesis:

      HIV-1 infected children hospitalized with severe co-infection either may be unsalvageable due
      to too far advanced immunosuppression/co-infection or may benefit from urgent ART.

      Secondary hypotheses:

      Urgent ART during an acute infection could potentially result in increased risk of immune
      reconstitution inflammatory syndrome (IRIS) or drug toxicities/interactions.

      Specific aims:

        1. To compare the 6 month all-cause mortality rate, incidence of immune reconstitution
           inflammatory syndrome (IRIS), and incidence of drug toxicity in HIV-1 infected children
           (≤ 12 years old) presenting to hospital with a serious infection randomized to urgent
           (&lt;48 hours) versus early ART (7-14 days).

        2. To determine co-factors for mortality, IRIS, and drug toxicity. Potential cofactors will
           include: baseline weight-for-age, height-for-age, weight-for-height (Z-scores), CD4,
           HIV-1 RNA, type of co-infection, age, rate of viral load and CD4 change following ART,
           immune activation markers, pathogen and HIV-1 specific immune responses.

      Secondary aim: To determine etiologies of IRIS and to compare immune reconstitution to HIV,
      TB, EBV and CMV following ART overall and in each trial arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children will be followed and compared for 6-month mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Evidence of Immune Reconstitution and Inflammatory Syndrome (IRIS)</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
    <description>Confirmed, possible or likely IRIS based on external independent review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potential Drug Toxicity</measure>
    <time_frame>6 months post-HAART initiation</time_frame>
    <description>Participants with adverse events that are deemed to be potentially related to medications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Immune Reconstitution Inflammatory Syndrome</condition>
  <arm_group>
    <arm_group_label>Urgent ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initiation of HAART 7-14 days after enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urgent ART</intervention_name>
    <description>Children will be started on HAART &lt;48 hours after enrollment.</description>
    <arm_group_label>Urgent ART</arm_group_label>
    <other_name>HAART regimens recommended by WHO and Kenya MOH.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early ART</intervention_name>
    <description>Children will be started on ART after stabilization 7-14 days after enrollment.</description>
    <arm_group_label>Early ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≤ 12 years old (reported)

          -  HIV-1 positive (for example, two rapid HIV-1 antibody tests for children &gt;18 months
             and not breastfeeding, or one HIV-1 DNA/RNA test for children ≤18 months or who are
             breastfeeding)

          -  Not currently receiving antiretroviral therapy (history of pMTCT does not affect
             eligibility)

          -  Eligible to receive ART, according to current WHO guidelines

          -  Caregiver plans to reside in study catchment area for at least 6 months (reported)

          -  Caregiver provides sufficient locator information

        Exclusion Criteria:

          -  Suspected meningitis, any other central nervous system infection, or encephalitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace John Stewart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JOOTRH</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kisumu District Hospital</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbagathi District Hospital</name>
      <address>
        <city>Nairobi</city>
        <zip>0202</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenyatta National Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2017</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Grace John-Stewart</investigator_full_name>
    <investigator_title>Professor, Global Health</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>IRIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>after primary and secondary outcomes are published</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Urgent ART</title>
          <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Early ART</title>
          <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Urgent ART</title>
          <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Early ART</title>
          <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0.9" upper_limit="6"/>
                    <measurement group_id="B2" value="1.8" lower_limit="0.8" upper_limit="4.5"/>
                    <measurement group_id="B3" value="1.9" lower_limit="0.8" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4%</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.5" lower_limit="9" upper_limit="18.3"/>
                    <measurement group_id="B2" value="17" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="B3" value="14.5" lower_limit="9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality</title>
        <time_frame>6 months post-HAART initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Urgent ART</title>
            <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Early ART</title>
            <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Evidence of Immune Reconstitution and Inflammatory Syndrome (IRIS)</title>
        <description>Confirmed, possible or likely IRIS based on external independent review</description>
        <time_frame>6 months post-HAART initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Urgent ART</title>
            <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Early ART</title>
            <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evidence of Immune Reconstitution and Inflammatory Syndrome (IRIS)</title>
          <description>Confirmed, possible or likely IRIS based on external independent review</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potential Drug Toxicity</title>
        <description>Participants with adverse events that are deemed to be potentially related to medications.</description>
        <time_frame>6 months post-HAART initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Urgent ART</title>
            <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Early ART</title>
            <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potential Drug Toxicity</title>
          <description>Participants with adverse events that are deemed to be potentially related to medications.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Urgent ART</title>
          <description>Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health.
Urgent ART: Children will be started on HAART &lt;48 hours after enrollment.</description>
        </group>
        <group group_id="E2">
          <title>Early ART</title>
          <description>Initiation of HAART 7-14 days after enrollment.
Early ART: Children will be started on ART after stabilization 7-14 days after enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Non-mortality SAE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IRIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grace John-Stewart</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 5434278</phone>
      <email>gjohn@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

